3-MeO-PCMo

From PsychonautWiki
(Redirected from 3meopcmo)
Jump to: navigation, search
Summary sheet: 3-MeO-PCMo
3-MeO-PCMo
3-MeO-PCMo.svg
Chemical Nomenclature
Substitutive name 3-MeO-PCMo
Systematic name 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine
Class Membership
Psychoactive class Dissociative
Chemical class Arylcyclohexylamine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.



Oral
Dosage
Threshold Common Heavy
50 - 100 - 200 - 300 - 400 mg
Light Strong
Threshold 50 - 100 mg
Light 100 - 200 mg
Common 200 - 300 mg
Strong 300 - 400 mg
Heavy 400 mg +
Duration
Total 5 - 6 hours
Onset 1 - 2 hours
Peak 2 - 3 hours
Offset 1 - 2 hours
After effects 2 - 3 hours









DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

3-MeO-PCMo (4-[1-(3-methoxyphenyl)cyclohexyl]morpholine) is a new morpholine analogue of 3-MeO-PCP. It is a dissociative NMDA receptor antagonist, sigma receptor[1] and anesthetic drug of the arylcyclohexylamine chemical class with a potency of less than 1/10th of that of 3-MeO-PCP.

This compound induces a state referred to as "dissociative anesthesia" when ingested and is therefore used as a recreational drug. 3-MeO-PCMo has recently become easily accessible through online research chemical vendors[2] where it is being sold as a designer drug.

Although very little is known about this compound, similar morpholine analogues of phencyclidine have been researched before.[3][4]

Chemistry

Generic structure of arylcyclohexylamine molecule

3-MeO-PCMo, or 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine, is classified as an arylcyclohexylamine drug. Ayrlcyclohexylamine drugs are named for their structures which include a cyclohexane ring bound to an aromatic ring along with an amine group at the same location. The aryl substituent of 3-MeO-PCMo is a phenyl ring with a methoxy (CH3-O-) substituent at R3, which is bound to a six-membered cyclohexyl ring. Bound at the same location on the cyclohexyl ring R1 is an amine group which is incorporated into a morpholine ring as R4.

Morpholine is a six-membered heterocyclic ring with an oxygen subsitutent at R1. 3-MeO-PCMo is a morpholine analogue to 3-MeO-PCP, which lacks an oxygen moiety in its six-membered amine ring (a piperidine ring instead of a morpholine ring).

Pharmacology

Further information: NMDA receptor antagonist

Due to the lack of research regarding the substance, all discussion regarding the pharmacology of it is purely based on its structure and subjective effect similarities to other arylcyclohexylamine dissociatives such as 3-MeO-PCP, PCP and MXE. With this in mind, 3-Meo-PCMo is thought to act as an NMDA receptor antagonist. NMDA receptors allow for electrical signals to pass between neurons in the brain and spinal column; for the signals to pass, the receptor must be open. Dissociatives close the NMDA receptors by blocking them. This disconnection of neurons leads to loss of feeling, difficulty moving, and eventually this substance's equivalent of the “K-hole.”

Subjective effects

The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. The listed effects should be taken with a grain of salt and will rarely (if ever) occur all at once, but heavier doses will increase the chances and are more likely to induce a full range of effects. Likewise, adverse effects become much more likely on higher doses and may include serious injury or death.

Physical effects
Child.svg

Visual effects
Eye.svg

Cognitive effects
User.svg

Experience reports

Anecdotal reports which describe the effects of this compound within this experience index include:


Potentially dangerous interactions

Although many psychoactive substances are safe on their own, they can become dangerous and even life-threatening when combined with other substances. The list below contains some common potentially dangerous combinations, but may not include all of them. Certain combinations may be safe in low doses of each but still increase the potential risk of death. Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

Prominent examples include PCP and its analogs 3-MeO-PCP, MXE, and the diarylethylamine dissociatives like diphenidine or ephenidine. There is also evidence that suggests that combining these two increases their neurotoxicity.[Controversial] Anecdotally, worsened comedowns are also commonly reported when these two classes of substances are combined.
  • Depressants - Because both depress the respiratory system, this combination can result in an increased risk of suddenly falling unconscious, vomiting and choking to death from the resulting suffocation. If nausea or vomiting occurs, users should attempt to fall asleep in the recovery position or have a friend move them into it.

Toxicity and harm potential

The toxicity and long-term health effects of recreational 3-MeO-PCMo use do not seem to have been studied in any scientific context and the exact toxic dosage is unknown. This is because 3-MeO-PCMo has very little history of human usage. Anecdotal evidence from people who have tried 3-MeO-PCMo within the community suggest that there do not seem to be any negative health effects attributed to simply trying this drug at low to moderate doses by itself and using it sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

It is strongly recommended that one use harm reduction practices when using this substance to ensure the administration of the intended dose.

Tolerance and addiction potential

As with other NMDA receptor antagonists, the chronic use of 3-MeO-PCMo can be considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.

Tolerance to many of the effects of 3-MeO-PCMo develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about 3 - 7 days for the tolerance to be reduced to half and 1 - 2 weeks to be back at baseline (in the absence of further consumption). 3-MeO-PCMo presents cross-tolerance with all dissociatives, meaning that after the consumption of 3-MeO-PCMo all dissociatives will have a reduced effect.

Urinary tract effects

In terms of its long-term health effects when used repeatedly and with excess for extended periods of time, 3-MeO-PCMo seems to exhibit almost identical bladder and urinary tract problems to those found within ketamine, MXE and other arylcyclohexylamines, but to an even more extreme extent. This is because 3-MeO-PCMo is 50% less potent than that of ketamine which means significantly more of the drug must be consumed in order to achieve the same effects. Symptoms of 3-MeO-PCMo-induced cystitis can become extremely serious and can be described as:

  • Urinary frequency - Urinary frequency is the need to empty the bladder every few minutes.
  • Urinary urgency - This can be described as a sudden and compelling need to urinate.
  • Urinary pressure - This is experienced as a constant sensation of fullness in the bladder that is unrelieved by urination.
  • Pelvic and bladder pain - Pain can develop suddenly and severely, particularly as the bladder fills with urine.
  • Hematuria - Hematuria is visible blood in the urine.
  • Incontinence - This is the leakage of urine.

All of these, however, can easily be avoided by simply not using 3-MeO-PCMo on a daily or even weekly basis and manually limiting one's usage of the substance.

Legal issues

Handcuffs-300px.png

This legality section is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

3-MeO-PCMo is currently thought to be a legal grey area drug worldwide and is easily accessible through the use of online research chemical vendors. However, this does not guarantee anyone to be immune from legal prosecution should they be found in possession of this substance as the legality is likely to vary from country to country.

  • United Kingdom - It is illegal to produce, supply, or import this drug under the Psychoactive Substance Act, which came into effect on May 26th, 2016.[5] While most arylcyclohexylamines are covered by a generic clause[6], the 1-morpholine group of 3-MeO-PCMo is outside of the definition. While the drug is still controlled under the Psychoactive Substances Act, simple possession (other than within a custodial institution) is not criminalised.

See also

External links

References

  1. Sigma compounds derived from phencyclidine: identification of PRE-084, a new, selective sigma ligand (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/1658302
  2. (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/21215770https://www.ncbi.nlm.nih.gov/pubmed/21215770
  3. Synthesis and determination of acute and chronic pain activities of 1-[1-(4-methylphenyl) (cyclohexyl)] morpholine as a new phencyclidine derivative in rats (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/21428243
  4. Discriminable effects of phencyclidine analogs evaluated by multiple drug (PCP versus OTHER) discrimination training (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/2498947
  5. Psychoactive Substances Act 2016 (Legislation.gov.uk) | http://www.legislation.gov.uk/ukpga/2016/2/contents/enacted
  6. The Misuse of Drugs Act 1971 (Amendment) Order 2013 (Legislation.gov.uk) | http://www.legislation.gov.uk/uksi/2013/239/introduction/made